ArticleArtificial organs2024
Outcomes of Impella 5.0 and 5.5 for cardiogenic shock: A single-center 137 patient experience.
Article in Artificial organs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Impella 5.5 Support in Severe Cardiogenic Shock: Outcomes From the First Spanish Multicentre Cohort in Heart Transplant Centres.Interdisciplinary cardiovascular and thoracic surgery · 2026Observational
- Article
- Impact of Prolonged Impella 5.5 Support on Post-Transplant Outcomes: An Institutional Study.Clinical transplantation · 2026Article
- Experts' recommendations for the management of adult patients with cardiogenic shock.Annals of intensive care · 2026Article
- Clinical outcomes following Impella escalation in cardiogenic shock: a single-centre case series highlighting the gap between haemodynamic improvement and survival.AME case reports · 2026Article
- Perioperative temporary microaxial left ventricular assist device support in patients with low ejection fraction undergoing coronary artery bypass grafting.Frontiers in cardiovascular medicine · 2026Article
- Surgically implanted temporary ventricular assist pump - "Impella 5.5".Indian journal of thoracic and cardiovascular surgery · 2025Review
- Temporary Mechanical Support in Cardiogenic Shock Secondary to Heart Failure: An Evolving Paradigm.Journal of personalized medicine · 2025Review
- Are there etiology-specific risk factors for adverse outcomes in patients on Impella 5.5 support?JTCVS open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThis study evaluated the outcomes of patients with cardiogenic shock (CS) supported with Impella 5.0 or 5.5 and identified risk factors for in-hospital mortality.
methodsAdults with CS who were supported with Impella 5.0 or 5.5 at a single institution were included. Patients were stratified into three groups according to their CS etiology: (1) acute myocardial infarction (AMI), (2) acute decompensated heart failure (ADHF), and (3) postcardiotomy (PC). The primary outcome was survival, and secondary outcomes included adverse events during Impella support and length of stay. Multivariable logistic regression was performed to identify risk factors for in-hospital mortality.
resultsOne hundred and thirty-seven patients with CS secondary to AMI (n = 47), ADHF (n = 86), and PC (n = 4) were included. The ADHF group had the highest survival rates at all time points. Acute kidney injury (AKI) was the most common complication during Impella support in all 3 groups. Increased rates of AKI and de novo renal replacement therapy were observed in the PC group, and the AMI group experienced a higher incidence of bleeding requiring transfusion. Multivariable analysis demonstrated diabetes mellitus, elevated pre-insertion serum lactate, and elevated pre-insertion serum creatinine were independent predictors of in-hospital mortality, but the etiology of CS did not impact mortality.
conclusionsThis study demonstrates that Impella 5.0 and 5.5 provide effective mechanical support for patients with CS with favorable outcomes, with nearly two-thirds of patients alive at 180 days. Diabetes, elevated pre-insertion serum lactate, and elevated pre-insertion serum creatinine are strong risk factors for in-hospital mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.